Propylisopropyltryptamine


Propylisopropyltryptamine, also known as N-propyl-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family. It reportedly produces hallucinogenic effects that resemble those of other related dialkyl tryptamine derivatives, although PiPT is reportedly relatively weak and short-lasting. It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.

Use and effects

According to Alexander Shulgin in his 1997 book TiHKAL, PiPT had not yet been evaluated.

Interactions

Chemistry

PiPT is short for N-propyl-N-isopropyltryptamine. PiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines

Analogues

s of PiPT include methylisopropyltryptamine, ethylisopropyltryptamine, diisopropyltryptamine, and dipropyltryptamine, among others.

Society and culture

Legal status

Canada

PiPT is not a controlled substance in Canada as of 2025.

United States

PiPT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.